AbbVie Inc. (ABBV)

AbbVie Inc. emerged as an independent biotechnology powerhouse following its strategic spin-off from Abbott Laboratories in 2013, quickly rising to become one of the most profitable drug manufacturers in the world. The company built its empire largely upon the staggering success of Humira, a groundbreaking biologic for rheumatoid arthritis and other autoimmune conditions that held the title of the world's highest-grossing drug for years. Anticipating the inevitable patent cliff for Humira, AbbVie executed highly aggressive and successful strategic moves to diversify its clinical pipeline. The company successfully launched next-generation immunology blockbusters Skyrizi and Rinvoq, which have rapidly captured massive market share. Furthermore, AbbVie made a massive leap into the highly lucrative medical aesthetics space through its massive acquisition of Allergan, securing the ubiquitous Botox brand. The company also maintains a very strong presence in hematologic oncology with highly effective drugs like Imbruvica and Venclexta, alongside an expanding portfolio of neuroscience treatments. Driven by extremely robust cash flow, aggressive internal R&D, and a commitment to a high-yield dividend, AbbVie remains a fiercely competitive heavyweight in the modern biopharma landscape.